June 10, 2022

From Eric's Desk

Pride month, Juneteenth…and ASCO

The topics this week are a bit disconnected, but sometimes you just can’t make a tidy package.

To begin with, I want to recognize and celebrate Pride month. The LGBTQ+ struggle has been long and, in many ways, uneven. There is no question that much progress has been made over the last three decades in the acceptance of LGBTQ+ members of our community and ensuring equity and inclusion for all. That said, we still have work ahead of us, particularly in some parts of our country and in many nations across the globe. And there is still prejudice and inequity in our own community that simply cannot be tolerated.

I also want to celebrate Juneteenth. This holiday commemorates the day in 1865 when enslaved people in Galveston Bay, Texas finally learned of the end of slavery. Juneteenth, Freedom Day, or Black Independence Day has been celebrated with religious services, parades, and picnics since that time and finally became a federal holiday in 2021. June 19th is also a day to remember how far we need to go before everyone shares equally in the full promise of those freedom proclamations. Yale Cancer Center and the Smilow Network are fully committed to eliminating cancer care disparities across Connecticut—you will be hearing more about this commitment and the plans we are developing in the months ahead.

And finally, there was the American Society of Clinical Oncology annual meeting. As has been the case in recent years, the advances in cancer care are abundant. There were promising results presented that could affect the lives of countless patients with cancer. Among others, new results shared in breast cancer, lung cancer, and GI cancers are practice changing. On a local level, our own Yale investigators shone brightly. Our faculty delivered innumerable presentations/posters, education sessions, and discussions. We should all be proud to be part of ASCO. Now with almost 46,000 members, ASCO has continued to embrace education, research, and quality as its pillar missions. ASCO has also become one of the strongest voices in the oncology arena for access to care, DEI, and the need to view cancer care and cancer research from a global perspective.

That’s all for today. I wish you a relaxing summer weekend. Be well.

Eric P. Winer, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Network

News Center

Breast Cancer Drug Trial Results in "Unheard-of" Survival Rates

Read More

Cancer Trials Give Immunotherapies a Boost, but Finding Patients is a Challenge

Read More
Announcements

Hematology Welcomes Two New Faculty

Yale Hematology is pleased to welcome Anish V. Sharda, MBBS, MPH, and Lourdes Maria Mendez, MD, PhD, as Assistant Professors of Medicine (Hematology). Both Dr. Sharda and Dr. Mendez will join Yale from Beth Israel Deaconess Medical Center (BIDMC) and will begin their tenure on August 1, 2022.

Dr. Sharda will care for patients as part of the Smilow Classic Hematology Program and has been named the 2022-23 Forget Fellow. He received his medical degree from B.P. Koiral Institute of Health Sciences and completed his residency at the University of Minnesota Medical Center and his fellowship at BIDMC. He received his MPH in General Epidemiology from the University of Michigan and currently holds a grant from the NIH to study, “Molecular Mechanisms Underlying Endothelial Weibel-Palade Body Biogenesis and Exocytosis.” Dr. Sharda’s clinical interests include the care of patients with bleeding and clotting disorders, platelet disorders, and anemia.

Dr. Mendez received her medical degree from Albert Einstein College of Medicine, as well as a PhD in Cell Biology. She completed her residency at Weill Cornell-New York Presbyterian and while a fellow in hematology/oncology at BIDMC, undertook a post-doctoral fellowship in cancer genetics. Most recently, Dr. Mendez was an Instructor of Medicine at Harvard Medical School and the Leukemia Program Leader at BIDMC. Dr. Mendez is dedicated to both the clinical care of patients with myeloid disorders, and translational research to identify novel therapeutics in high-risk myeloid neoplasms and improve clinical outcomes for patients.

American Society of Hematology Selects Yale Cancer Center for Innovative Fellowship Training Program

Yale Cancer Center has been selected by the American Society of Hematology (ASH) to participate in a new fellowship training program that will foster the development of innovative clinical research projects.

Yale’s Winer Begins His ASCO Presidency

Read More

Lung Cancer Patients who Took Experimental Drug combo Lived Longer

Read More

This Drug Could Transform Breast Cancer Treatment

Read More
Society of Hematology (ASH) for the ASH Hematology-Focused Fellowship Training Program (HFFTP), an initiative to address the need to expand the hematology workforce. The program supports the launch of 10 new hematology-focused fellowship tracks at nine academic institutions across the country to provide education, mentorship, and research opportunities for fellows interested in pursuing careers in hematology.

Led by Alfred Lee, MD, PhD, and Robert Bona, MD, the Yale HFFTP draws upon the diverse clinical and scholarly strengths of Yale and its numerous interdisciplinary programs to provide an entirely novel curriculum with robust clinical training and unparalleled research opportunities in all aspects of classical hematology. The fellowship provides broad exposure to a wealth of collaborative research programs, interdisciplinary pathways, and opportunities for advanced degree training.

**Learn More**

**YCC and Smilow Climate Survey**
Yale Cancer Center and Smilow Cancer Hospital are committed to building a diverse and welcoming community, one in which we all thrive together. We recognize that an inclusive and representative workforce is a key to our mission of preventing and treating cancer for everyone. We also recognize that historic inequities at our institution and in science and medicine more broadly may hinder us in reaching these goals.

For this reason, we will conduct a climate survey to hear from all of you across Yale Cancer Center and Smilow Cancer Hospital, about your experiences and your view of diversity, equity, and inclusion. The data will be analyzed by an independent consultant (The Barthwell Group), and your answers will remain completely anonymous. We urge you to be candid – only by truly understanding barriers faced by some in our community will we be able to dismantle those barriers. We also urge you to participate! The results will be most meaningful with high participation.

The survey for Yale Cancer Center members, trainees, and employees will launch on June 15th and will come as an email from Dr. Winer’s office. The survey for Smilow Cancer Hospital employees will follow later in June, coming through health system email.

Access to the survey will be with a link embedded in the survey. It should take no more than 15 minutes to complete, even if you have a lot to say. You can complete it on your phone, and you don’t need to complete it in one sitting. Please take these few minutes to make sure we hear your voice!

**Notables**

**Mehra Golshan, MD, MBA**, Deputy Chief Medical Officer for Surgical Services and Critical Care, and Director of Surgical Oncology and Surgical Hematology.

**Drug Combination Shows Promise for Treating Pancreatic Neuroendocrine Tumors**

**The Missing Part of America's Pandemic Response**

**FIT TO FIGHT** How pottering in the garden could boost cancer survival chances
Mehra Golshan, MD, MBA, Deputy Chief Medical Officer for Surgical Services and Professor of Surgery (Oncology), has been awarded a Service Excellence Award by Healthnetwork Foundation in recognition of outstanding clinical care. The award includes a $10,000 donation to Yale Cancer Center in Dr. Golshan’s honor to support his research efforts.

Benjamin L. Judson, MD, MBA, a member of Yale Cancer Center’s Cancer Prevention Program, whose research interests include investigating outcomes and quality in head and neck cancer therapy, has been appointed the Charles W. Ohse Professor of Surgery (Otolaryngology) at Yale School of Medicine.

Nikhil Joshi, PhD, Assistant Professor of Immunobiology and a member of Yale Cancer Center’s Cancer Immunology Research Program, is a recipient of the 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research. The prize provides early career, New York area scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking.

Chen Liu, MD, PhD, Chair and Anthony N. Brady Professor of Pathology and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, has been elected to his second term as chair of the Practice & Management Committee of the Association of Pathology Chairs (APC). APC is a nonprofit that serves as the voice of academic pathology departments in the United States and Canada by providing leadership and advocacy for the discipline of pathology and allowing academic departments to meet the demands of their missions of medical education, research, and practice.

Giulia Biancon, PhD, a postdoctoral associate in the laboratory of Stephanie Halene, MD, PhD, was recognized with a Best Poster Award at the 27th Annual Meeting of the RNA Society in Boulder, CO.

Tamar Taddei, MD, Associate Professor of Medicine (Digestive Diseases), has assumed the role of Chief of Gastroenterology at the Veterans Affairs (VA) Connecticut Healthcare System.

Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program welcomes Arnaud Augert, PhD, Assistant Professor of Pathology. Dr. Augert has built a multidisciplinary research program that combines cell biology, mouse genetics, and cutting-edge molecular biology to elucidate the transcriptional and epigenetic mechanisms underlying small cell lung cancer (SCLC) initiation, progression, and response to therapies. His research laboratory will attempt to make significant conceptual advances in their understanding of tumor development with the goal of unlocking more effective therapeutic strategies for patients.

Diversity, Equity, and Inclusion

The Doctor’s Art: Fighting for Empowerment and Equity
In this podcast, Dr. Pamela Kunz, Associate Professor of Medicine (Medical Oncology)
Cancer Disparities Progress Report
Earlier this week, the American Association for Cancer Research (AACR) presented the AACR Cancer Disparities Progress Report 2022. The goal of the report is to increase public awareness and understanding of cancer health disparities, highlight areas of recent progress in reducing cancer health disparities and provide specific recommendations for achieving health equity. Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Cancer Center Director for Experimental Therapeutics, is a member of the AACR Cancer Disparities Committee.

Celebrating Juneteenth
The city of New Haven will honor Juneteenth with a four-day celebration featuring a variety of events, hosted by the Official Juneteenth Coalition of Greater New Haven, the International Festival of Arts & Ideas, and the New Haven Museum, held June 17-20.

Employee Profile: Kwasi Boateng
Kwasi Boateng, MS, is the Clinical Trials Team Manager for Therapeutic Radiology and Head & Neck Oncology within the Yale Cancer Center Clinical Trials Office. Kwasi has been with Yale for 3 ½ years but prior to joining the CTO, he worked as a CRA at Columbia University and was a study coordinator for the Montefiore Health System in NYC for a combined 4 years. He received his master’s degree in Human Nutrition from Columbia University Vagelos College of Physicians and Surgeons.

In his current role, Kwasi helps ensure that his team has all they need to successfully conduct clinical trials here at Yale. Kwasi believes his role is inherent of the three basic ethical principles outlined in the Belmont Report which are respect for persons, beneficence, and justice. According to Kwasi there are three separate groups who he equally serves – the organization, the staff, and the patient. He also serves as a conduit between the investigators and the sponsor(s) of a new study or clinical trial. In preparation for a new study, Kwasi ensures that it is feasible to hold the study at Yale and

Read More
that everything is in place to conduct the trial safely.

Kwasi manages a team of five personnel between the Therapeutic Radiology and Head & Neck teams, with some overlap. With each new study that comes in, he emphasizes that every team member plays a critical role to get a study set up and ready for patients.

Working in clinical trials came naturally for Kwasi. As a graduate student at Columbia, his mentor worked in clinical research, and invited Kwasi to join his research thus igniting a new career pursuit for Kwasi. Further confirmation came at Montefiore, when one of the first clinical trials Kwasi worked on benefited the father of a very close friend.

“I’ve done benchwork for a long time, but to see its impact – from bench to person, we are making sure clinical practice continues to improve.”

He adds, “Our role (in the Clinical Trials Office) is to keep patients safe, and ensure data collected for each study is of the utmost quality. Receiving feedback from patients, knowing that we helped provide different options for them is gratifying. This what motivates me and brings me fulfillment.”

Recent Publications


Congratulations to Lynn T. Tanoue, MD, MBA, Professor of Medicine (Pulmonary Medicine), recipient of the American Thoracic Society (ATS) Thoracic Oncology Lifetime Achievement Award in recognition of her mentorship, devoted career in thoracic oncology and lung cancer screening and diagnosis, and dedication to the ATS.
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Read More

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
New England Journal of Medicine, Online ahead of print.
Read More

Herbst RS, Wang M, Chen L.
When Immunotherapy Meets Surgery in Non-small Cell Lung Cancer
Cancer Cell, Online ahead of print.
Read More

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Journal of Clinical Oncology, Online ahead of print.
Read More

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A
Journal of Clinical Oncology, Online ahead of print.
Read More

Brongiel S, Rychalsky KL, Luon D, Johnson AR, Price C, Abdelghany O.
Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events
Annals of Pharmacotherapy, Online ahead of print.
Read More

Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands
Journal of Medical Chemistry, Online ahead of print.
Read More

Craig M. Crews, PhD, John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, Pharmacology, and Management, has received the 2022 Connecticut Medal of Technology from the Connecticut Academy of Science and Engineering.
Congratulations, Dr. Crews!
Read More

Tune in to Yale Cancer Answers to hear Dr. Sidi Chen discuss the role of Supercharged Cancer-Fighting T Cells in increasing an immune cell’s ability to target and kill cancer cells. Listen on Connecticut Public Radio or download our podcast from iTunes.
Read More

Our Smilow Cancer Hospital Care Center in Trumbull recognized three of our nursing stars earlier today for their recent graduations! Congratulations to Janelle D’Ellia, MSN, Michelle Laspino, DNP-FNP, and Jennifer Fernandes, BSN.
Read More
Researchers at Yale Cancer Center have provided hope to cancer patients worldwide. Recent advances have included new therapies for the care of breast, lung, and head and neck cancers, and tackling disparities. We continue to unlock discoveries in many other cancers, and develop new and better approaches to preventing, diagnosing, and treating cancer. We understand that Cancer Research Saves Lives!
Renzulli JF 2nd, Brito J 3rd, Kim IY, Broccoli I. 
A Meta-analysis on the Use of Radiotherapy after Prostatectomy: Adjuvant versus Early Salvage Radiation 
Prostate International, 10(2):80-84. 
Read More

Plain Language Summary of Results from the JAVELIN Bladder 100 Study: Avelumab Maintenance Treatment for Advanced Urothelial Cancer 
Future Oncology, 18(19):2361-2371. 
Read More

Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. 
SYK and ZAP70 Kinases In Autoimmunity And Lymphoid Malignancies 
Cellular Signaling, 94:110331. 
Read More

Presley CJ, Kaur K, Han L, Soulos PR, Zhu W, Corneau E, O'Leary JR, Chao H, Shamas T, Rose MG, Lorenz KA, Levy CR, Mor V, Gross CP. 
Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer 
Read More

Strazzabosco M, Cabibbo G, Colombo M. 
Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future 
Gastroenterology, 162(7):2106-2108. 
Read More

Mathew AT, Jain B, Dee EC, Johnson J, Chino F. 
Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers 
Read More

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial 
Read More

Health-Related Quality of Life Findings from the JAVELIN Bladder 100 Study: Avelumab Maintenance Treatment for Advanced Urothelial Cancer 
Read More

Join us in-person on Monday, June 13, 5:30-9pm, for @OncLiveSOSS Breast Cancer, hosted by @DrEricWiner, Director @YaleCancer, Physician-in-Chief @SmilowCancer Network.

Dr. Lajos Pusztai will present an analysis of #KEYNOTE522 highlighting "Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early #TNBC" at #ASCO22 today at 10:33amCDT in HallD1.

That's a wrap on #ASCO22! A few more of our favorite pics from a weekend full of exciting science, reconnecting with colleagues, and meeting new friends.

Stay tuned for a @medpagetoday discussion with @DrRoyHerbstYale @nievamd and Dr. Sarah Goldberg sharing...
A Group Approach To Growing As A Principal Investigator
Current Biology, 32(11):R498-R504.

Single-Cell Antigen-Specific Landscape Of CAR T Infusion Product
Identifies Determinants Of CD19-Positive Relapse In Patients With ALL
Science Advances.

Funding and Award Opportunities

Accelerating Cancer Screening (AxCS) (HRSA-22-154)
This funding will support health centers to increase equitable access to cancer screening and referral for care and treatment by enhancing education, case management, outreach, and other enabling services, in partnership or coordination with NCI-designated Cancer Centers that will deploy outreach specialists and patient navigators for populations served by health centers. This funding supports President Joe Biden’s call to action on cancer screening and early detection as part of the Administration’s Cancer Moonshot initiative to reduce the cancer death rate by at least 50% over the next 25 years and support families living with and surviving cancer.

Application Deadline: June 15, 2022

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 and R21)
The purpose of these FOAs is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 16, 2022

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)
This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Application Deadline: June 17, 2022

DoD Ovarian Cancer Research Program
Clinical Trial Award - LOI Due: June 22, 2022
DoD Rare Cancers Research Program (RCP) Awards
- **Concept Award** - LOI Due: July 18, 2022
- **Idea Development Award** - Preproposal Due: June 22, 2022
- **Resource and Community Development Award** - Preproposal Due: June 22, 2022

Lasker Clinical Research Scholars Program (Si2/R00)
This program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.
**Application Deadline:** June 24, 2022

Paul Calabresi Career Development Award for Clinical Oncology (K12)
The purpose of this award is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This FOA allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
**Application Deadline:** June 25, 2022

NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with Small Cell Lung Cancer (SCLC) Research Grant Opportunity
The intent of this RFP is to encourage NCCN Member Institutions to submit LOIs describing concepts and ideas for evaluating barriers to guideline concordant care in LS-SCLC and/or ES-SCLC and developing healthcare quality improvement initiatives to enhance patient care and outcomes.
**Letter of Intent Due:** June 27, 2022

2022 Yale Cancer Center Internal Pilot Grants Competition
These grants will support all potential areas of innovative cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research. Relevance of proposed research to our catchment area priorities is also an important consideration.

The YCC Center for Community Engagement and Health Equity is available for consultation on community engagement, health disparities, and catchment relevance (Jessica.Lewis@yale.edu).
**Application Deadline:** July 1, 2022
Damon Runyon Cancer Research Foundation: Runyon-Rachleff Innovation Award 2022
This award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

**Internal Deadline:** July 1, 2022

Read More

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)
This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

**Application Deadline:** July 5, 2022

Read More

Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21)
This FOA solicits grant applications proposing to utilize bacteria, archaeabacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.

**Application Deadline:** July 5, 2022

Read More

Cancer Control Research in Persistent Poverty Areas (U54)
Through this FOA, the NCI invites applications for Cancer Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas.

**Application Deadline:** July 6, 2022

Read More

Pancreatic Cancer Research Program
The FY22 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program (PCARP) to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

- Idea Development Award
- Translational Research Partnership Award

**Preproposals Due:** July 8, 2022

Read More

DoD Melanoma Research Program Awards
These awards invest in research focusing on the prevention, detection, diagnosis, and treatment of melanoma for the benefit of Service members, Veterans, their families, and the American public.

- **Focused Program Award – Rare Melanomas – Letter of Intent Due:** September 14, 2022
- **Melanoma Academy Scholar Award – Letter of Intent Due:** September 14, 2022
- **Mid-Career Accelerator Award – Letter of Intent Due:** September 14, 2022

Learn More

Neuroendocrine Conference
**June 15; 4:00 PM**
*Pituitary/Adrenal Journal Club*
Brian Wojcick, MD, MPH

Learn More

Smilow Shares
**June 15; 6:30 PM**
*Patient & Family Cancer Survivor Series: Fear of Recurrence*
Tara Sant, MD | Maura Harrigan, MS, RDN, CSO | Angela Khairallah, LCSW | Javin Brita, PA | Scott Capozza, PT, MSPT

Learn More

Therapeutic Radiology Grand Rounds
**June 16; 9:00 AM**
*Addressing the Invisible: Understanding the Disparities Faced by Sexual and Gender Minoritized People with Cancer*
Don S. Dizon, MD, FACP, FASCO

Learn More

Life Support
**June 16; 9:30 AM**
*Clinical Trials for MBC*
Maryam Lustberg, MD, MPH | Neal Fischbach, MD | Dr. Stephanie Graff | Dr. Alvaro Menendez | Sheila Marie Johnson

Learn More

MB&B Informal Seminar
**June 16; 11:00 AM**
*The SMN Complex Drives Structural Changes in snRNAs to Enable snRNP Assembly*
David Stanek, PhD

Learn More

Cancer Genetics and Prevention Seminar
**June 16; 2:30 PM**

Learn More

Health Equity Fireside Chat with Yale Women
**June 16; 3:00 PM**
Barbara Burtness, MD | Andrea Silber, MD | Kim Blenman, PhD, MS | Akosua Barthwell Evans PhD, JD

Learn More

Yale Cancer Center Chalk Talk
**June 15; 11:00 AM**
*Translating the Language of the Tumor Immune Microenvironment to Improved Patient Outcomes*
Michael Chiorazzi, MD, PhD

Learn More

Neuroendocrine Conference
**June 15; 4:00 PM**
*Pituitary/Adrenal Journal Club*
Brian Wojcick, MD, MPH

Learn More

Smilow Shares
**June 15; 6:30 PM**
*Patient & Family Cancer Survivor Series: Fear of Recurrence*
Tara Sant, MD | Maura Harrigan, MS, RDN, CSO | Angela Khairallah, LCSW | Javin Brita, PA | Scott Capozza, PT, MSPT

Learn More

Therapeutic Radiology Grand Rounds
**June 16; 9:00 AM**
*Addressing the Invisible: Understanding the Disparities Faced by Sexual and Gender Minoritized People with Cancer*
Don S. Dizon, MD, FACP, FASCO

Learn More

Life Support
**June 16; 9:30 AM**
*Clinical Trials for MBC*
Maryam Lustberg, MD, MPH | Neal Fischbach, MD | Dr. Stephanie Graff | Dr. Alvaro Menendez | Sheila Marie Johnson

Learn More

MB&B Informal Seminar
**June 16; 11:00 AM**
*The SMN Complex Drives Structural Changes in snRNAs to Enable snRNP Assembly*
David Stanek, PhD

Learn More

Cancer Genetics and Prevention Seminar
**June 16; 2:30 PM**

Learn More
The Mark Foundation for Cancer Research: 2023 Mark Foundation Endeavor Award
These awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are $3 million grants disbursed over a three-year term.
**Internal Deadline:** July 13, 2022

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
The purpose of this FOA is to invite applications for TCORS to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the FDA Center for Tobacco Products.
**Application Deadline:** July 14, 2022

Damon Runyon Cancer Research Foundation: Damon Runyon-Dale F. Frey Award for Breakthrough Scientists 2022
The Damon Runyon Fellowship identifies the nation’s top postdoctoral fellows and provides funding that enables them to complete their training under the mentorship of a leading senior scientist and encourages them to follow their own bold ideas. To catapult their research careers—and their impact on cancer—the Foundation will make an additional investment in these exceptional individuals by selecting them as recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists.
**Internal Deadline:** July 15, 2022

Innovations for Veterans QuickFire Challenge: Lung Cancer & Physical Trauma
Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the unique healthcare needs of the military community including lung cancer and physical trauma.
**Application Deadline:** July 15, 2022

DoD Breast Cancer Research Program Transformative Breast Cancer Consortium Award
This award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
**Pre-application Due:** August 3, 2022

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44)

This FOA solicits SBIR applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.

**Application Deadline:** August 6, 2022

Gabrielle's Angel Foundation
The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment. Of interest are innovative clinical and basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies. Focus is on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3-5 year period.

**Internal Submission Deadline:** August 8, 2022

AACR-Lung Cancer Initiative at Johnson & Johnson - Stimulating Therapeutic Advances through Research Training (START)
These grants, which will provide support to postdoctoral or clinical research fellows from underrepresented groups combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work.

**Application Deadline:** August 18, 2022

Small Business Transition Grant For Early Career Scientists (R42)
Through this FOA, the NCI, National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.

**Application Deadline:** August 22, 2022

Survivor Series
June 22; 6:30 PM
The Cost of Cancer
Rachel Greenup, MD, MPH | Gary Soffer, MD, FAAP | Emily Rock | Lauren Coletta

General Internal Medicine Grand Rounds
June 23; 7:30 AM
Lung Cancer Screening in 2022
Lynn Tanoue, MD, MBA

Therapeutic Radiology Grand Rounds
June 23; 9:00 AM
TBN
Kevin Du, MD, PhD, MSCI

Cancer Genetics and Prevention Seminar
June 23; 2:30 PM

Center for GI Cancers Weekly Seminar
June 23; 4:15 PM
Nitya Raj, MD

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications